Genomic Organization & Cytogenetic Locus: 6-exon gene spanning ~85 kb on chromosome 12q23.2 driven by two alternative promoters (P1 using exon 1 and P2 using exon 2, both regulated by Growth Hormone-activated STAT5B response elements) and alternative 3-prime splicing of exons 5 and 6 that generates systemic liver IGF-1Ea alongside mechanical-stretch-induced local muscle splice variant IGF-1Ec (mechano-growth factor, MGF), all yielding the identical 70-residue mature B-C-A-D domain peptide.
Cellular & Tissue Expression Profile: Hepatic hepatocytes synthesize ~75% of circulating endocrine plasma IGF-1 (where it circulates in a 150 kDa ternary complex with IGFBP-3 and acid-labile subunit IGFALS that extends its plasma half-life to 12–15 hours), while chondrocytes, osteoblasts, skeletal muscle fibers, and brain neurons synthesize local autocrine/paracrine IGF-1.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Binds the heterotetrameric alpha2-beta2 receptor tyrosine kinase IGF1R (and hybrid IGF1R/INSR receptors) with sub-nanomolar affinity, phosphorylating IRS-1/IRS-2 to activate the PI3K-AKT1-mTORC1 cascade (stimulating ribosomal protein translation and satellite cell proliferation while phosphorylating and excluding FOXO1 and FOXO3 from the nucleus to suppress muscle atrogenes) and the RAS-RAF-MEK-ERK mitogenic cascade.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Homozygous loss-of-function mutations in human IGF1 cause severe intrauterine and postnatal growth retardation, microcephaly, sensorineural deafness, and insulin resistance (unlike GH1/GHR deficiency, which spares prenatal growth because fetal IGF-1 is GH-independent); across model organisms and human centenarian cohorts, evolutionarily conserved attenuation of the somatotropic GH-IGF1-IGF1R axis activates FOXO3 and extends healthspan.
Therapeutic & Clinical Pharmacology: Recombinant human IGF-1 (mecasermin / Increlex) is FDA-approved for severe primary IGF-1 deficiency (including Laron syndrome / GHR deficiency), while its N-terminal tripeptide Gly-Pro-Glu analog trofinetide (Daybue) is approved for Rett syndrome (MECP2).